← Back to Screener
Tango Therapeutics, Inc. (TNGX)
Price$20.22
Value ScoreD
Growth ScoreA
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)77.41%
Price vs S&P 500 (4W)-12.15%
VGM Score65.83
Market Capitalization$2.92B
All Metrics
Book Value / Share (Quarterly)$2.72
P/TBV (Annual)3.08x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)35.89%
Cash Flow / Share (Quarterly)$-0.99
Price vs S&P 500 (YTD)120.06%
Net Profit Margin (TTM)-151.15%
EPS (TTM)$-0.83
10-Day Avg Trading Volume2.53M
EPS Excl Extra (TTM)$-0.83
EPS (Annual)$-0.87
ROI (Annual)-65.15%
Net Profit Margin (5Y Avg)-268.70%
Cash / Share (Quarterly)$2.63
Revenue Growth QoQ (YoY)363.61%
ROA (Last FY)-41.23%
Revenue Growth TTM (YoY)39.04%
EBITD / Share (TTM)$-0.92
ROE (5Y Avg)-33.14%
Operating Margin (TTM)-165.91%
Cash Flow / Share (Annual)$-1.22
P/B Ratio7.47x
P/B Ratio (Quarterly)7.62x
Net Income / Employee (Annual)$-741,600
EV / Revenue (TTM)41.61x
ROA (TTM)-33.44%
EPS Incl Extra (Annual)$-0.87
Current Ratio (Annual)7.00x
Quick Ratio (Quarterly)26.51x
3-Month Avg Trading Volume3.16M
52-Week Price Return476.07%
Revenue / Employee (TTM)$416,000
Tangible BV / Share (Quarterly)$2.72
P/S Ratio (Annual)46.88x
Asset Turnover (Annual)0.13x
52-Week High$28.41
Operating Margin (5Y Avg)-288.19%
EPS Excl Extra (Annual)$-0.87
26-Week Price Return85.33%
Quick Ratio (Annual)6.78x
13-Week Price Return20.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)27.38x
Enterprise Value$2.77B
Asset Turnover (TTM)0.26x
Revenue / Employee (Annual)$455,400
Pretax Margin (Annual)-162.85%
Cash / Share (Annual)$2.39
3-Month Return Std Dev107.15%
Net Income / Employee (TTM)$-782,700
ROE (Last FY)-65.15%
EPS Basic Excl Extra (Annual)$-0.87
Receivables Turnover (TTM)36.53x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.83
Receivables Turnover (Annual)12.43x
ROI (TTM)-41.54%
P/S Ratio (TTM)43.98x
Pretax Margin (5Y Avg)-268.32%
Revenue / Share (Annual)$0.54
Tangible BV / Share (Annual)$2.83
Price vs S&P 500 (52W)451.70%
Year-to-Date Return128.22%
5-Day Price Return-12.47%
EPS Normalized (Annual)$-0.87
ROA (5Y Avg)-20.59%
Net Profit Margin (Annual)-162.85%
Month-to-Date Return-8.01%
Cash Flow / Share (TTM)$-1.08
EBITD / Share (Annual)$-0.94
Operating Margin (Annual)-178.39%
ROI (5Y Avg)-33.14%
EPS Basic Excl Extra (TTM)$-0.83
P/TBV (Quarterly)2.78x
P/B Ratio (Annual)1.67x
Pretax Margin (TTM)-150.99%
Book Value / Share (Annual)$1.84
Price vs S&P 500 (13W)11.89%
Beta1.23x
Revenue / Share (TTM)$0.40
ROE (TTM)-41.54%
52-Week Low$3.12
vGradeD
gGradeA
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.32est. -0.32
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.31
4.29
4.29
4.28
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TNGXTango Therapeutics, Inc. | D | A | A | $20.22 |
| LLYEli Lilly & Co. | D | B | B | $1131.42 |
| JNJJohnson & Johnson | D | C | B | $232.77 |
| ABBVABBVIE INC. | D | C | C | $227.23 |
| MRKMerck & Co., Inc. | C | C | B | $120.79 |
| NVSNovartis AG | C | C | C | $149.16 |
| AZNAstraZeneca PLC | D | B | C | $185.95 |
| NVONovo-Nordisk A/S | B | B | B | $42.96 |
| ABTAbbott Laboratories | C | C | D | $91.07 |
| PFEPfizer Inc. | B | C | C | $26.04 |
| BMYBristol-Myers Squibb Co. | B | C | B | $57.27 |
About
Tango Therapeutics is a precision oncology company developing novel targeted therapies for cancer. The company is advancing PRMT5 inhibitors including TNG462 for non-CNS cancers such as pancreatic and lung cancer, and TNG456, a brain-penetrant inhibitor for CNS cancers including glioblastoma. The pipeline also targets CoREST pathways.